SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-162636
Filing Date
2023-06-07
Accepted
2023-06-07 17:00:58
Documents
17
Period of Report
2023-06-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d481426d8k.htm   iXBRL 8-K 32096
2 EX-1.1 d481426dex11.htm EX-1.1 231335
3 EX-5.1 d481426dex51.htm EX-5.1 10068
4 EX-99.1 d481426dex991.htm EX-99.1 8905
8 GRAPHIC g481426g0607031051968.jpg GRAPHIC 3020
9 GRAPHIC g481426img001.jpg GRAPHIC 7517
  Complete submission text file 0001193125-23-162636.txt   496419

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA dawn-20230606.xsd EX-101.SCH 2856
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE dawn-20230606_lab.xml EX-101.LAB 18737
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dawn-20230606_pre.xml EX-101.PRE 11711
11 EXTRACTED XBRL INSTANCE DOCUMENT d481426d8k_htm.xml XML 3485
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 650 484-0899
Day One Biopharmaceuticals, Inc. (Filer) CIK: 0001845337 (see all company filings)

IRS No.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40431 | Film No.: 23999720
SIC: 2834 Pharmaceutical Preparations